ABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing diabetic retinopathy. The American Academy of Ophthalmology classifies diabetic retinopathy into non‐proliferative diabetic retinopathy and proliferative diabetic retinopathy, distinguished by the absence or presence of neovascularization, respectively. Complications such as diabetic macular edema, retinal detachment, and irreversible vision loss further underscore the need for effective therapies. Current treatments include laser photocoagulation, vitrectomy, and anti‐vascular endothelial growth factor agents. This narrative review evaluates established pharmacotherapy and explores emerging therapies targeting novel pathways such as inflammation, oxidative stress, and vascular stability. Investigational agents, including integrin inhibitors, gene therapies, and small‐molecule antagonists, alongside innovative delivery systems such as topical formulations and sustained‐release implants, offer the potential to enhance treatment efficacy, patient adherence, and overall outcomes in diabetic retinopathy. By examining these advancements, including innovative delivery systems, this review aims to inform practitioners about the evolving landscape of pharmacotherapy for diabetic retinopathy.
Clements et al. (Sun,) studied this question.